We are live on ! Find out more
JB

Julian Baker Baker Bros. Advisors

AUM $20B
1-Year Est. Return 154.41%
 

Julian Baker is co-managing member of Baker Bros. Advisors, a firm renowned for deep specialization in biotechnology and life sciences. The firm is known for concentrated positions, long holding periods, and scientific diligence that goes well beyond typical generalist research. Baker Bros. filings are closely watched by healthcare investors for signals in clinical-stage and commercial biotech.

This Fund
S&P 500
This Quarter Est. Return
+28.34%
1 Year Est. Return
+154.41%
3 Year Est. Return
+448.58%
5 Year Est. Return
+670.61%
10 Year Est. Return
+4,743.65%
AUM
$15.2B
AUM Growth
+$1.87B
Cap. Flow
+$90.5M
Cap. Flow %
0.6%
Top 10 Hldgs %
84.66%
Holding
125
New
12
Increased
14
Reduced
21
Closed
27

Top Buys

Rank Stock Value
1
PRNB
Principia Biopharma Inc. Common Stock
PRNB
+$50.5M
2
AMRN
Amarin Corp
AMRN
+$43.1M
3
INSM icon
Insmed
INSM
+$26M
4
ACAD icon
Acadia Pharmaceuticals
ACAD
+$19M
5
GWPH
GW Pharmaceuticals Plc American Depositary Shares
GWPH
+$10.8M

Top Sells

Rank Stock Value
1
BLUE
bluebird bio
BLUE
+$22.4M
2
PHXM
PHAXIAM Therapeutics S.A.. American Depositary Shares
PHXM
+$20.8M
3
HALO icon
Halozyme
HALO
+$14.6M
4
EXEL icon
Exelixis
EXEL
+$11M
5
XNCR icon
Xencor
XNCR
+$11M

Sector Composition

Rank Sector Weight
1 Healthcare 99.42%
2 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
EXEL icon
101
Exelixis
EXEL
$13.4B
– –
-513,410
Closed -$11M
CBIO
102
Crescent Biopharma
CBIO
$637M
– –
-2,912
Closed -$4.7M
MDWD icon
103
MediWound
MDWD
$171M
– –
-32,286
Closed -$1.56M
MGNX icon
104
MacroGenics
MGNX
$261M
– –
-217,695
Closed -$4.5M
NTRA icon
105
Natera
NTRA
$47.9B
– –
-228,676
Closed -$4.3M
RIGL icon
106
Rigel Pharmaceuticals
RIGL
$857M
– –
-104,161
Closed -$2.95M
RNAC icon
107
Cartesian Therapeutics
RNAC
$304M
– –
-3,125
Closed -$1.24M
TNXP icon
108
Tonix Pharmaceuticals
TNXP
$215M
– –
0
– -$3.11M
VNDA icon
109
Vanda Pharmaceuticals
VNDA
$319M
– –
-310,354
Closed -$5.91M
LUMO
110
DELISTED
Lumos Pharma, Inc. Common Stock
LUMO
– –
-56,364
Closed -$2.42M
TRVN
111
DELISTED
Trevena, Inc.
TRVN
– –
-1,520
Closed -$1.37M
TTOO
112
DELISTED
T2 Biosystems, Inc
TTOO
– –
-20
Closed -$774K
ACOR
113
DELISTED
Acorda Therapeutics
ACOR
– –
-1,443
Closed -$4.97M
JNCE
114
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
– –
-100,000
Closed -$766K
AERI
115
DELISTED
Aerie Pharmaceuticals
AERI
– –
-60,155
Closed -$4.06M
NBRV
116
DELISTED
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
– –
-3,753
Closed -$3.27M
TTPH
117
DELISTED
Tetraphase Pharmaceuticals, Inc.
TTPH
– –
-46,750
Closed -$3.34M
PGNX
118
DELISTED
Progenics Pharmaceuticals Inc
PGNX
– –
-979,016
Closed -$7.87M
STML
119
DELISTED
Stemline Therapeutics, Inc.
STML
– –
-44,524
Closed -$715K
BTX.WS
120
DELISTED
BioTime Inc Warrants (Expiring October 1, 2018)
BTX.WS
– –
-20,084
Closed -$1K
BDSI
121
DELISTED
BioDelivery Sciences International, Inc.
BDSI
– –
-210,021
Closed -$620K
1 2 3 4
5

Similar funds

ASRS
Arizona State Retirement System Phoenix, Arizona $19.9B AUM 44.71% 1-Year Est. Return
FWIA
Fort Washington Investment Advisors Cincinnati, Ohio $19.9B AUM 22.19% 1-Year Est. Return
CWP
Capital Wealth Planning Naples, Florida $20B AUM 25.34% 1-Year Est. Return
SFA
Sequoia Financial Advisors Akron, Ohio $20.1B AUM 24.77% 1-Year Est. Return
MGP
M&G plc London, United Kingdom $20.1B AUM 16.62% 1-Year Est. Return
JAM
Jupiter Asset Management London, United Kingdom $20.2B AUM 29.18% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $19.7B AUM 39.39% 1-Year Est. Return
Select Equity Group
Select Equity Group New York $20.2B AUM 17.52% 1-Year Est. Return

Julian Baker's Q3 2018 Portfolio in Review

As of Q3 2018, Julian Baker held 125 positions worth $15.2B, up 14% from $13.3B the previous quarter. Its ten largest holdings account for 85% of the portfolio.

Julian Baker's Q3 2018 filing shows 12 new, 14 increased, 21 reduced and 27 closed positions. Its largest new stake was Principia Biopharma Inc. Common Stock: 1,787,807 shares worth $52.2M. The largest sale was bluebird bio, an estimated $22.4M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 99% a quarter earlier, followed by Technology.

  • Julian Baker's largest Q3 2018 buy was Principia Biopharma Inc. Common Stock: 1,787,807 shares worth $52.2M.
  • Julian Baker added most to Amarin Corp in Q3 2018, an estimated $43.1M increase.
  • Julian Baker's biggest Q3 2018 reduction was bluebird bio, cutting an estimated $22.4M.
  • Julian Baker fully exited Exelixis in Q3 2018, selling an estimated $11M.
  • Julian Baker's ten largest holdings make up 85% of its $15.2B portfolio in Q3 2018.
  • Julian Baker opened 12 new positions and closed 27 in Q3 2018.
  • Julian Baker's portfolio value rose 14% quarter-over-quarter to $15.2B.

Based on Baker Bros. Advisors's 13F filing for Q3 2018, filed 14 Nov 2018.